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The ﬁbrosarcomatous variant of dermatoﬁbrosarcoma protuberans (DFSP) represents an uncommon form of DFSP which has a
higher risk of local recurrence and distant metastases than ordinary DFSP.
The aim of our study is to investigate clinicopathologic characteristics, treatment modalities and prognostic factors of nine cases of
transformed DFSP admitted in Salah Azaiez Institute between 2002 and 2009.
They were ﬁve men and four women. Median age at diagnosis was 52 years (35–87 years). The lesions were located on the abdominal
wall (three cases), the upper limb (two cases), the back (two cases), the lower limb (one case) and the chest wall (one case). Tumor size
ranged from 25 mm to 150 mm. After diagnosis, six patients were treated by wide local excision with marginsP2 cm, two patients had
local excision without deﬁned margins and one patient had incomplete local excision. Three patients underwent radiotherapy because of
either cramped or unknown limits. Local recurrence was diagnosed in 5 cases and distant metastasis occurred in one patient.
Fibrosarcomatous DFSP exhibits more aggressive behavior than DFSP. Their similar clinical presentation requires histopathological
diﬀerentiation for prognosis. Treatment is based on wide local excision, radiation and targeted therapy.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Dermatoﬁbrosarcoma protuberans (DFSP) is a locally
aggressive ﬁbrohistiocytic tumor of intermediate malig-
nancy with a great potential of recurrences and a small risk
of distant metastasis. The ﬁbrosarcomatous variant of
DFSP represents an uncommon form of DFSP in which
the prognosis is closely linked to the ﬁbrosarcomatous
component.
The aim of our study is to investigate clinicopathologic
characteristics, treatment modalities and prognostic factors
of 9 cases of transformed DFSP.
2. Methods
We have compiled nine patients from Salah Azaiez
Institut of Tunisia during the period from 2002 to 2009.
Those patients had histologically proven ﬁbrosarcomatous
dermatoﬁbrosarcoma protuberans (FS-DFSP).
Treatment modalities and outcomes were analyzed
retrospectively.
3. Results
We analyzed the clinicopathologic features of a series of
nine patients presenting FS-DFSP (Table 1). Six patients
have been treated initially in other hospitals and three were
seen ﬁrst in our department.
They were ﬁve men and four women, and their age at
diagnosis ranged from 35 to 87 years (mean, 52). All
patients had a history of a slowly growing painless mass.
The lesions were located on the abdominal wall (three
cases), the upper limb (two cases), the back (two cases),
the lower limb (one case) and the chest wall (one case).
Tumor size ranged from 25 mm to 150 mm (mean, 86 mm).
In ﬁve patients FS-DFSP occurred as a recurrence of
classic dermatoﬁbrosarcoma, and the number of recur-
rences varies from 1 to 6. The remaining patients presented
this type of lesion for the ﬁrst time.
After diagnosis, six patients were treated by wide local
excision with margins P2 cm, two patients had local
excision without deﬁned margins and one patient had
incomplete local excision. Three patients underwent
radiotherapy because of either cramped or unknown limits.
Follow-up ranged from one to 144 months. Recurrences
occurred in ﬁve cases at a median of 2.4 years. All these
patients were treated by wide local excision, and one of
them had local radiotherapy. In one case, lung metastasis
was diagnosed and treated by chemotherapy. The patient
was lost of view in poor condition.4. Discussion
The DFSP aﬀects predominately adults between 20 and
50 years. A slight male predominance has been reported
(Rutgers et al., 1992), as shown in our study; 5 men and
4 women. There is no diﬀerence in anatomic location
between DFSP and ﬁbrosarcomatous DFSP. Similar to
our series, it is seen mainly on the trunk (42–72%) and
the proximal extremities (16–30%) (Lemm et al., 2009).
The ﬁbrosarcomatous transformation of DFSP is excep-
tional. In 1951, Penner reported a case of metastasizing
DFSP containing areas that were histologically indistin-
guishable from ﬁbrosarcoma (Penner, 1951).
As FS-DFSP is clinically indistinguishable from ordi-
nary DFSP, its diagnosis is established histologically. It is
characterized by more spindle cells, greater number of
nuclei and increased mitotic rate. Immunohistochemically,
a strong CD34 positivity is an important feature for the
diagnosis of DFSP. However, in the sarcomatous cases,
the CD34 reactivity can be weak and this can be explained
by the loss of expression of CD34 during the tumor diﬀeren-
tiation (Weiss and Goldblum, 2001).
The standard therapeutic approach used for the treat-
ment of the DFSP is wide and deep local excision including
the underlying fascia with margins P2 cm (Voth et al.,
2011). These margins have been respected in 6 patients in
our series. Some authors suggest the use of Moh’s micro-
graphic surgery in order to achieve negative resection mar-
gins and simultaneously preserve the uninvolved tissue
from resection (Llombart et al., 2011).
The extent of the initial resection is the most signiﬁcant
prognostic factor for relapse. In our study, ﬁve patients
presented local recurrence. In four cases, margins were
P2 cm in anatomopathologic examination. Ding and al
suggested a high recurrence rate (89%) in cases of ﬁbrosar-
comatous transformation, but the adequacy of surgical
excisions was not made clear (Ding et al., 1989). Mentzel
et al. and Pizarro et al. documented a recurrence rate of
59%, but a minority of the patients received wide local exci-
sion and treatment details were not provided (Mentzel
et al., 1998). One of the largest studies by Goldblun et al.
found no prognostic diﬀerences between conventional
DFSP and DFSP containing sarcoma treated by wide local
excision (Goldblum et al., 2000). These desperate results
are due to small sample sizes and inadequate treated
patients included. In a retrospective review of 122 patients
with DFSPat the University of Texas MD Anderson
Cancer Center in Houston, ﬁbrosarcomatous change was
signiﬁcantly associated with local recurrence and patients
with a higher percentage of FS change (25%) carried a
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2011).
DFSP has been proposed to be a relatively radiosensi-
tive tumor and radiation should be considered as an adju-
vant to resection if margins are positive, and wider excision
is not feasible due to anatomic limitations. Some authors
also recommended the use of radiotherapy after wide resec-
tion in the ﬁbrosarcomatous subtype, even with negative
margins, to improve local control and reduce the risk of
recurrence postoperatively (Farma et al., 2010 and
Williams et al., 2014). We indicated radiotherapy in
patients who had local excision without deﬁned margins
(2 patients). Recently, targeted therapy (Imatinib) has
shown very good results. It is accepted that the use of this
drug is indicated in patients with unresectable, locally
advanced, recurrent or metastatic disease (Han et al.,
2009). It can also be used in tumor shrinkage prior to
surgery, avoiding loss of functions and cosmetic defects.
The clinical eﬃcacy of Imatinib crucially depends on the
presence of t(17,22) in the individual tumor and/or its
metastases with objective response rates in classic DFSP
and FS-DFSP harboring t(17,22) approaching 50%
(Rutkowski et al., 2010).
The metastatic capacity makes DFSP a true sarcoma,
although the rate of metastases is less than 5% (McPeak
et al., 1967). Distant metastases usually occur only after
multiple local recurrences, mostly in the lungs or bones.
The distant metastasis reported in our study was in the
lung and occurred after only one recurrence, 3 years after
surgery.
5. Conclusion
Fibrosarcomatous DFSP exhibits more aggressive
behavior than DFSP. Their similar clinical presentation
requires histopathological diﬀerentiation for prognosis
which appears to be worse in DFSP with FS change with
higher risks of local recurrence, metastasis, and
death. Additional studies are needed to deﬁne optimal
management but will be challenging given the rarity of this
entity.Conﬂict of interest
None declared.
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